

## EARLY TERMINATIONS GRANTED—Continued

[12/01/2020 12:00:00 a.m., 12/31/2020 12:00:00 a.m.]

## 12/28/2020

20210205 .....	G	Caesars Entertainment, Inc.; William Hill PLC; Caesars Entertainment, Inc.
20210689 .....	G	Biogen Inc.; Sage Therapeutics, Inc; Biogen Inc.
20210690 .....	G	Thoma Bravo Fund XIII-A, L.P.; Venafi, Inc; Thoma Bravo Fund XIII-A, L.P.
20210691 .....	G	Nasdaq, Inc.; Verafin Holdings, Inc.; Nasdaq, Inc.

## 12/31/2020

20210651 .....	G	Stephen Griggs; AdaptHealth Corp.; Stephen Griggs.
20210652 .....	G	SkyKnight Aero Holdings, LLC; AdaptHealth Corp.; SkyKnight Aero Holdings, LLC.
20210653 .....	G	Peloton Equity AeroCare SPV I, L.P.; AdaptHealth Corp.; Peloton Equity AeroCare SPV I, L.P.

**FOR FURTHER INFORMATION CONTACT:**

Theresa Kingsberry (202-326-3100), Program Support Specialist, Federal Trade Commission Premerger Notification Office, Bureau of Competition, Room CC-5301, Washington, DC 20024.

By direction of the Commission.

**April J. Tabor,**

*Secretary.*

[FR Doc. 2021-03183 Filed 2-17-21; 8:45 am]

**BILLING CODE P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Centers for Disease Control and Prevention****Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—Funding Opportunity Announcement (FOA), RFA OH-21-003, Extension of the World Trade Center Health Registry (U50); Amended Notice of Meeting**

Notice is hereby given of a change in the meeting of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—Funding Opportunity Announcement (FOA), RFA OH-21-003, Extension of the World Trade Center Health Registry (U50), April 13, 2021; 9:00 a.m.–6:00 p.m., EDT in the original FRN.

The virtual meeting was published in the **Federal Register** on Monday, January 11, 2021, Volume 86, Number 6, page 1976.

The meeting on April 13, 2021 is being amended to change the time and should read as follows:

*Time:* 1:00 p.m.–3:00 p.m., EDT.

The meeting is closed to the public.

**FOR FURTHER INFORMATION CONTACT:**

Marilyn Ridenour B.S.N., M.B.A., M.P.H., C.P.H., C.I.C., CAPT, USPHS, Scientific Review Officer, CDC, National Institute for Occupational Safety and Health, 1095 Willowdale Road, Mailstop

1811, Morgantown, West Virginia 26505, Telephone (304) 285-5879.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2021-03231 Filed 2-17-21; 8:45 am]

**BILLING CODE 4163-18-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****National Center for Advancing Translational Sciences; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Center for Advancing Translational Sciences Special Emphasis Panel; CTSA Revision Award.

*Date:* March 9, 2021.

*Time:* 12:00 p.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, Room 1078, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Rahat (Rani) Khan, Ph.D., Scientific Review Officer, Office of Scientific Review, National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, Room 1078, Bethesda, MD 20892, 301-894-7319 [khanr2@csr.nih.gov](mailto:khanr2@csr.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)

Dated: February 11, 2021.

**David W. Freeman,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2021-03190 Filed 2-17-21; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****Prospective Grant of an Exclusive Patent License: Autologous Therapy for the Treatment of Autoimmune Disease Using Chimeric Antigen Receptors Targeting CD19**

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Kyverna Therapeutics (“Kyverna”) located in Berkeley, CA.

**DATES:** Only written comments and/or complete applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before March 5, 2021 will be considered.

**ADDRESSES:** Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: David A Lambertson, Ph.D., Senior Technology Transfer Manager, at Telephone (240)-276-5530 or Email: [david.lambertson@nih.gov](mailto:david.lambertson@nih.gov).

**SUPPLEMENTARY INFORMATION:**

**Intellectual Property**

The following represents the intellectual property to be licensed under the prospective agreement:

(A) U.S. Provisional Patent Application 62/006,313 entitled "Chimeric Antigen Receptors Targeting CD-19" [HHS Ref. E-042-2014-0-US-01], PCT Patent Application PCT/US2015/033473 entitled "Chimeric Antigen Receptors Targeting CD-19" [HHS Ref. E-042-2014-0-PCT-02], Australian Patent 2015270912 entitled "Chimeric Antigen Receptors Targeting CD-19" [HHS Ref. E-042-2014-0-AU-03], Canadian Patent Application 2951045 entitled "Chimeric Antigen Receptors Targeting CD-19" [HHS Ref. E-042-2014-0-CA-04], Chinese Patent Application 201580033802.5 entitled "Chimeric Antigen Receptors Targeting CD-19" [HHS Ref. E-042-2014-0-CN-05], European Patent 3149044 entitled "Chimeric Antigen Receptors Targeting CD-19" [HHS Ref. E-042-2014-0-EP-06] (validated in Germany [HHS Ref. E-042-2014-0-DE-19], Spain [HHS Ref. E-042-2014-0-ES-20], France [HHS Ref. E-042-2014-0-FR-21], the United Kingdom [HHS Ref. E-042-2014-0-GB-22], Italy [HHS Ref. E-042-2014-0-IT-23], and Ireland [HHS Ref. E-042-2014-0-IE-24], and lodged in Hong Kong [E-042-2014-0-HK-16]), Israeli Patent Application 249305 entitled "Chimeric Antigen Receptors Targeting CD-19" [HHS Ref. E-042-2014-0-IL-07], Indian Patent Application 291647041047 entitled "Chimeric Antigen Receptors Targeting CD-19" [HHS Ref. E-042-2014-0-IN-08], Japanese Patent Application 2016-571017 entitled "Chimeric Antigen Receptors Targeting CD-19" [HHS Ref. E-042-2014-0-JP-09], South Korean Patent Application 2016-7036828 entitled "Chimeric Antigen Receptors Targeting CD-19" [HHS Ref. E-042-2014-0-KR-10], Mexican Patent Application MX/a/2016/015834 entitled "Chimeric Antigen Receptors Targeting CD-19" [HHS Ref. E-042-2014-0-MX-11], New

Zealand Patent Application 727167 entitled "Chimeric Antigen Receptors Targeting CD-19" [HHS Ref. E-042-2014-0-NZ-12], Saudi Arabian Patent Application 516380406 entitled "Chimeric Antigen Receptors Targeting CD-19" [HHS Ref. E-042-2014-0-SA-13], Singaporean Patent Application 11201609960Q entitled "Chimeric Antigen Receptors Targeting CD-19" [HHS Ref. E-042-2014-0-SG-14], United States Patent 10,287,350 entitled "Chimeric Antigen Receptors Targeting CD-19" [HHS Ref. E-042-2014-0-US-15], United States Patent Application 16/360,281 entitled "Chimeric Antigen Receptors Targeting CD-19" [HHS Ref. E-042-2014-0-US-17], New Zealand Patent Application 764530 entitled "Chimeric Antigen Receptors Targeting CD-19" [HHS Ref. E-042-2014-0-NZ-18], European Patent Application 20197459.9 entitled "Chimeric Antigen Receptors Targeting CD-19" [HHS Ref. E-042-2014-0-EP-25], Australian Patent Application 2020267211 entitled "Chimeric Antigen Receptors Targeting CD-19" [HHS Ref. E-042-2014-0-AU-26], and Japanese Patent Application XXX entitled "Chimeric Antigen Receptors Targeting CD-19" [HHS Ref. E-042-2014-0-JP-27], and all continuing U.S. and foreign patents/patent applications for the technology family.

The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.

The prospective exclusive license territory may be worldwide and the field of use may be limited to the following:

"The development, production and commercialization of an anti-CD19 targeting chimeric antigen receptor (CAR)-based immunotherapy using autologous (meaning one individual is both the donor and the recipient) T lymphocytes transfected using a lentivirus, wherein the vector expresses a CAR having at least:

- (1) The complementary determining region (CDR) sequences of the anti-CD19 antibody known as Hu19;
- (2) a CD8a hinge and transmembrane domain;
- (3) and a CD28z T cell signaling domain; for the treatment of autoimmune diseases."

This technology discloses the development of chimeric antigen receptors that recognize the CD19 cell surface protein. CD19 is expressed on the cell surface of several autoimmune disease cells, including lupus nephritis. For many autoimmune diseases there are no FDA-approved therapies, underscoring that there is an unmet need. The development of an autoimmune disease therapeutic

targeting CD19 will benefit public health by providing a treatment for patients who may not have any options.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a completed license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: February, 4, 2021.

**Richard U. Rodriguez,**

*Associate Director, Technology Transfer Center, National Cancer Institute.*

[FR Doc. 2021-03222 Filed 2-17-21; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Administration for Children and Families**

**Proposed Information Collection Activity; Legal Services for Unaccompanied Alien Children (New Collection)**

**AGENCY:** Office of Refugee Resettlement, Administration for Children and Families, Department of Health and Human Services.

**ACTION:** Request for Public Comment.

**SUMMARY:** The Office of Refugee Resettlement (ORR), Administration for Children and Families (ACF), U.S. Department of Health and Human Services (HHS), is inviting public comment on the proposed collection. The request consists of several forms that allow the Unaccompanied Alien Children (UAC) Program to provide legal services to UAC.

**DATES:** *Comments due within 60 days of publication.* In compliance with the requirements of Section 3506(c)(2)(A) of